Fibrates and cholestasis

Cited by (318)

Items 101–200 of 318

1. Editor’s Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner
   Youcai Zhang, Andrew J. Lickteig, Iván L. Csanaky, Curtis D. Klaassen · 2017 · Toxicological Sciences
2. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis
   Nan Shen, Jielu Pan, Hongyu Miao, Haiyan Zhang, Lianjun Xing, Xiao Feng Yu · 2021 · Annals of Palliative Medicine
3. A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis
   Kaihui Zhang, Yufeng Yao, Meiqi Wang, Fangle Liu, Qian Wang, Huanhuan Ma, Yuanyuan Xie, Yunxia Ma, Pengyu Dai, Chenchen Zhu et al. · 2021 · Phytomedicine
4. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis
   Matteo Tardelli, Francesca Virginia Bruschi, Claudia Daniela Fuchs, Thierry Claudel, Nicole Auer, Victoria Kunczer, Maximilian Baumgartner, Onne A. H. O. Ronda, Henkjan J. Verkade, Tatjana Stojaković et al. · 2019 · Hepatology
5. Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease
   Michael A Trauner, Saul J. Karpen, Paul A. Dawson · 2025 · Hepatology
6. Screening and validation of biomarkers for cadmium-induced liver injury based on targeted bile acid metabolomics
   Meng Tian, Jun Yan, Honglong Zhang, Yuhui Wei, Mingtong Zhang, Zhi Rao, Mingkang Zhang, Haiping Wang, Yanping Wang, Xun� Li · 2022 · Environmental Pollution
7. The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism
   Yuqing Sun, Luyong Zhang, Zhenzhou Jiang · 2023 · Basic & Clinical Pharmacology & Toxicology
8. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis
   Wei Lin, Jun-xi Wang, Yi-juan Liu · 2024 · Systematic Reviews
9. Novel Aspects in the Management of Cholestatic Liver Diseases
   Olivier Chazouillères · 2016 · Digestive Diseases
10. Schisandrol B protects against cholestatic liver injury by inhibiting pyroptosis through pregnane X receptor
    Hangfei Liang, Yang Xiao, Huilin Li, Xinhui Wang, Hai‐Guo Su, Xuan Li, Jianing Tian, Chenghui Cai, Min Huang, Huichang Bi · 2022 · Biochemical Pharmacology
11. Atherosclerosis: The Involvement of Immunity, Cytokines and Cells in Pathogenesis, and Potential Novel Therapeutics
    Chang Su, Yongzheng Lu, Zeyu Wang, Jiacheng Guo, Yachen Hou, Xiaofang Wang, Zhen Qin, Jiamin Gao, Zhaowei Sun, Yichen Dai et al. · 2022 · Aging and Disease
12. Targeted bile acids and gut microbiome profiles reveal the hepato-protective effect of WZ tablet (Schisandra sphenanthera extract) against LCA-induced cholestasis
    Dongshun Li, Quanfei Huang, Lihuan Guan, Huizhen Zhang, Xi Li, Kaili Fu, Yixin Chen, Jian‐Bo Wan, Min Huang, Huichang Bi · 2020 · Chinese Journal of Natural Medicines
13. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
    Ludovico Abenavoli, Anna Caterina Procopio, Sharmila Fagoonee, Rinaldo Pellicano, Marco Carbone, Francesco Luzza, Pietro Invernizzi · 2020 · Diseases
14. Dolomiaea souliei ethyl acetate extract protected against α-naphthylisothiocyanate-induced acute intrahepatic cholestasis through regulation of farnesoid x receptor-mediated bile acid metabolism
    Fancheng Meng, Wei Zong, Xiaodong Wei, Yun-Yi Tao, Guowei Wang, Zhihua Liao, Min Chen · 2021 · Phytomedicine
15. Regulation of Liver Energy Balance by the Nuclear Receptors Farnesoid X Receptor and Peroxisome Proliferator Activated Receptor α
    Kang Ho Kim, David D. Moore · 2017 · Digestive Diseases
16. The Protective Roles of PPARα Activation in Triptolide-Induced Liver Injury
    Dandan Hu, Qi Zhao, Yan Cheng, Xue-Rong Xiao, Jian‐Feng Huang, Yan Qu, Xian Li, Yingmei Tang, Wei-Min Bao, Jinhui Yang et al. · 2019 · Toxicological Sciences
17. Kinsenoside Alleviates 17α-Ethinylestradiol-Induced Cholestatic Liver Injury in Rats by Inhibiting Inflammatory Responses and Regulating FXR-Mediated Bile Acid Homeostasis
    Jiaxiong Ming, Qianqian Xu, Limin Gao, Yanfang Deng, Jie Yin, Qun Y. Zhou, Qingyi Tong, Yonghui Zhang · 2021 · Pharmaceuticals
18. Protective effects of petroleum ether extracts of Herpetospermum caudigerum against α-naphthylisothiocyanate-induced acute cholestasis of rats
    Wen-rui Cao, Jing-Qiu Ge, Xin Xie, Meng-lin Fan, Xu-dong Fan, Hong Wang, Zhaoyue Dong, Zhihua Liao, Xiaozhong Lan, Min Chen · 2017 · Journal of Ethnopharmacology
19. Targeted Metabolomics Reveals a Protective Role for Basal PPARα in Cholestasis Induced by α-Naphthylisothiocyanate
    Manyun Dai, Huiying Hua, Hante Lin, Gang-Ming Xu, Xiaowei Hu, Fei Li, Frank J. Gonzalez, Aiming Liu, Julin Yang · 2018 · Journal of Proteome Research
20. Cholestatic liver diseases: An era of emerging therapies
    Hrishikesh V. Samant, Wuttiporn Manatsathit, David F. Dies, Hosein M. Shokouh-Amiri, Gazi B. Zibari, Moheb Boktor, Jonathan Steven Alexander · 2019 · World Journal of Clinical Cases
21. Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel
    Domenico Alvaro, Guido Carpino, Antonio Craxı̀, Annarosa Floreani, Antonio Moschetta, Pietro Invernizzi · 2020 · Liver International
22. Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
    Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Michael Trauner · 2025 · Hepatology
23. The Role of Fibrates in Primary Biliary Cholangitis
    Christophe Corpechot · 2019 · Current Hepatology Reports
24. Imperatae rhizoma-Hedyotis diffusa Willd. herbal pair alleviates nephrotic syndrome by integrating anti-inflammatory and hypolipidaemic effects
    Wei Zou, Yaqian Dong, Shicong Yang, Linna Gong, Yan Zhang, Birui Shi, Lei La, Lan Yu Tang, Menghua Liu · 2021 · Phytomedicine
25. Validation of MAPK signalling pathway as a key role of paeoniflorin in the treatment of intrahepatic cholestasis of pregnancy based on network pharmacology and metabolomics
    Jiawei Wang, Jianxia Wen, Xiao Ma, Ju Yang, Zhao Zhang, Shuying Xie, Shizhang Wei, Manyi Jing, Haotian Li, Liwei Lang et al. · 2022 · European Journal of Pharmacology
26. Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora
    Xiaolei Miao, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen · 2023 · Lipids in Health and Disease
27. β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor
    Thomas Klag, Maria Thomas, Dirk Ehmann, Lioba F. Courth, Daniela Mailänder‐Sánchez, Thomas S. Weiß, Rania Dayoub, Kerstin Abshagen, Brigitte Vollmar, Wolfgang Erwin Thasler et al. · 2018 · Frontiers in Immunology
28. An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis
    Mengzhi Zou, Aizhen Wang, Jiajie Wei, Heng Cai, Zixun Yu, Luyong Zhang, Xinzhi Wang · 2021 · International Immunopharmacology
29. Glycocholic acid aggravates liver fibrosis by promoting the up-regulation of connective tissue growth factor in hepatocytes
    Zihang Yuan, Jie Wang, Haoran Zhang, Yuanyuan Chai, Yunxia Xu, Yingying Miao, Ziqiao Yuan, Luyong Zhang, Zhenzhou Jiang, Qinwei Yu · 2022 · Cellular Signalling
30. Molecular mechanisms of hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: Role of FXR and Nrf2 pathways
    Peng Cao, Jun Gan, Sanlan Wu, Yixin Hu, Bin Xia, Xiaoyue Li, Hongan Zeng, Bingyu Cheng, Huifan Yu, Fei Li et al. · 2023 · Food and Chemical Toxicology
31. A novel model construction of lithocholic acid-induced cholestasis and transcriptome analysis in snakehead fish (Channa argus)
    Yidi Kong, Min Li, Changge Xia, Xinyu Liu, Guiqin Wang · 2021 · Aquaculture
32. Dietary Macroalgae Saccharina japonica Ameliorates Liver Injury Induced by a High-Carbohydrate Diet in Swamp Eel (Monopterus albus)
    Chuanqi Yu, Lu Wang, Wanghe Cai, Wenping Zhang, Zhonghua Hu, Zirui Wang, Zhuqing Yang, Mo Peng, Huanhuan Huo, Yazhou Zhang et al. · 2022 · Frontiers in Veterinary Science
33. BM-MSCs overexpressing the Numb enhance the therapeutic effect on cholestatic liver fibrosis by inhibiting the ductular reaction
    Yannan Xu, Wenping Xu, Xu Zhang, Dan‐Yang Wang, Xin-rui Zheng, Wei Liu, Jiamei Chen, Gao‐Feng Chen, Chenghai Liu, Ping Liu et al. · 2023 · Stem Cell Research & Therapy
34. Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway
    Shicheng Fan, Yue Gao, Pengfei Zhao, Guomin Xie, Yanying Zhou, Yang Xiao, Xuan Li, Shuaishuai Zhang, Frank J. Gonzalez, Aijuan Qu et al. · 2024 · Acta Pharmaceutica Sinica B
35. Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice
    Julien Gautherot, Thierry Claudel, Frans J.C. Cuperus, Claudia Daniela Fuchs, Thomas Falguières, Michael A Trauner · 2018 · Journal of Lipid Research
36. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models
    Ning Fan, Ke Meng, Yu‐Qing Zhang, Yong Hu, Donghua Li, Qiaoying Gao, Jianhua Wang, Yanning Li, Shangwei Wu, Yunfeng Cui · 2020 · Lipids in Health and Disease
37. Update on pharmacotherapies for cholestatic liver disease
    Ahmad Hassan Ali, James H. Tabibian, Keith D. Lindor · 2016 · Hepatology Communications
38. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis
    Chang Wang, Ying Shi, Xiaomei Wang, Heming Ma, Quan Liu, Yanhang Gao, Junqi Niu · 2022 · Frontiers in Immunology
39. Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
    Rozanne C. de Veer, Maria C. van Hooff, Christophe Corpechot, Douglas Thorburn, Pietro Invernizzi, Willem J. Lammers, Harry L.A. Janssen, Pier Maria Battezzati, Frederik Nevens, Keith D. Lindor et al. · 2022 · The American Journal of Gastroenterology
40. Oleuropein-Induced Acceleration of Cytochrome P450–Catalyzed Drug Metabolism: Central Role for Nuclear Receptor Peroxisome Proliferator-Activated Receptor α
    Foteini Malliou, Christina E. Andriopoulou, Frank J. Gonzalez, Aristeidis Kofinas, Alexios‐Léandros Skaltsounis, Maria Konstandi · 2021 · Drug Metabolism and Disposition
41. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
    Vincenzo Ronca, Marco Carbone, Francesca Bernuzzi, Federica Malinverno, Hani S. Mousa, M. Eric Gershwin, Pietro Invernizzi · 2017 · Expert Review of Clinical Immunology
42. Downregulation of proinflammatory liver gene expression by Justicia spicigera and kaempferitrin in a murine model of obesity-induced by a high-fat diet
    Samantha Alejandra Real-Sandoval, Gustavo F. Gutiérrez‐López, Aarón Domínguez‐López, Norma Paniagua‐Castro, Maria Monica Michicotl-Meneses, María Eugenia Jaramillo‐Flores · 2020 · Journal of Functional Foods
43. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
    Shinya Okishio, Kanji Yamaguchi, Hiroshi Ishiba, Nozomi Tochiki, Kota Yano, Aya Takahashi, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Yu Liu et al. · 2020 · Scientific Reports
44. The protective role of hydrophilic tetrahydroxylated bile acids (THBA)
    Jonathan A. Sheps, Renxue Wang, Jian‐She Wang, Victor Wei Teik Ling · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
45. Exploring the potential of andrographis paniculata and its bioactive compounds in the management of liver diseases: A comprehensive food chemistry perspective
    Sunil Kumar, Kshirod Kumar Ratha, Sheetal Jaiswal, Meda Mruthyumjaya Rao, Rabinarayan Acharya · 2024 · Food Chemistry Advances
46. Forsythiaside-A improved bile-duct-ligation-induced liver fibrosis in mice: The involvement of alleviating mitochondrial damage and ferroptosis in hepatocytes via activating Nrf2
    Qian Guo, Zeqi Wu, Keke Wang, Jionghua Shi, Mengjuan Wei, Bin Lu, Zhenlin Huang, Lili Ji · 2024 · Free Radical Biology and Medicine
47. The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor a activation in valproic acid-induced liver injury
    Yiyi Ma, Minglu Wang, Shuaishuai Guo, Tong Li, Xiaodong Liu, Limei Zhao · 2022 · Frontiers in Pharmacology
48. Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    You Sun Kim, Edward Hurley, Yoojeong Park, Sungjin Ko · 2023 · Intestinal Research
49. The anti-hyperlipidemic effects of Poria cocos (Schw.) Wolf extract: Modulating cholesterol homeostasis in hepatocytes via PPARα pathway
    Xinyu Zhang, Wei Lin, Shuyue Lei, Siqi Zhang, Yujie Cheng, Xijing Chen, Yang Lu, Di Zhao, Yongjie Jessica Zhang, Chaorui Guo · 2023 · Journal of Ethnopharmacology
50. Machine learning-based characterization of the gut microbiome associated with the progression of primary biliary cholangitis to cirrhosis
    Qi Wang, Xiaomeng Tang, Wenying Qiao, Lina Sun, Han Shi, Dexi Chen, Bin Xu, Yanmin Liu, Juan Zhao, Chunyang Huang et al. · 2024 · Microbes and Infection
51. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis
    Lu Wang, Keshuai Sun, Ai TIAN, Yansheng LIU, Miao Zhang, Xinmin Zhou, Ying Han · 2022 · Minerva Medica
52. Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
    Fangling Zhang, Xiaolin Xiao, Yong Li, Hefei Wu, Xinyu Deng, Yinxiao Jiang, Wenwen Zhang, Jian Wang, Xiao Ma, Yanling Zhao · 2022 · Frontiers in Pharmacology
53. Natural product-based screening led to the discovery of a novel PXR agonist with anti-cholestasis activity
    Dong Huang, Ying-Yuan Zhao, Ruimin Wang, Wei Li, Fang-Yu Yuan, Xue‐Long Yan, Xiao Yang, Gui‐Hua Tang, Sheng Yin, Huichang Bi · 2021 · Acta Pharmacologica Sinica
54. Da-Chai-Hu-Tang Protects From Acute Intrahepatic Cholestasis by Inhibiting Hepatic Inflammation and Bile Accumulation via Activation of PPARα
    Shihao Xu, Xi Qiao, Peike Peng, Ziyi Zhu, Yaoting Li, Mengyuan Yu, Long Chen, Yin Cai, Jin Xu, Xinwei Shi et al. · 2022 · Frontiers in Pharmacology
55. Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER α degradation
    Zhen Zhou Zhao, Lulu Yang, Qiao-Lei Wang, Jinfa Du, Zu‐Guo Zheng, Yan Jiang, Ping Li, Hui‐Jun Li · 2022 · Cell Biology and Toxicology
56. Suppression of Hepatic PPARα in Primary Biliary Cholangitis Is Modulated by miR-155
    Monika Adamowicz, Agnieszka Kempińska‐Podhorodecka, Joanna Abramczyk, Jesús M. Bañales, Piotr Milkiewicz, Małgorzata Milkiewicz · 2022 · Cells
57. Lathyrane Diterpenoids as Novel hPXR Agonists: Isolation, Structural Modification, and Structure–Activity Relationships
    Dong Huang, Ruimin Wang, Wei Li, Ying-Yuan Zhao, Fang-Yu Yuan, Xue‐Long Yan, Ye Chen, Gui‐Hua Tang, Huichang Bi, Sheng Yin · 2021 · ACS Medicinal Chemistry Letters
58. Emerging drugs for the treatment of primary sclerosing cholangitis
    Nadir Abbas, Mohammed Nabil Quraishi, Palak Jitendrakumar Trivedi · 2021 · Current Opinion in Pharmacology
59. Spermine-Related DNA Hypermethylation and Elevated Expression of Genes for Collagen Formation are Susceptible Factors for Chemotherapy-Induced Hand-Foot Syndrome in Chinese Colorectal Cancer Patients
    Mingming Li, Jiani Chen, Shaoqun Liu, Xiaomeng Sun, Huilin Xu, Qianmin Gao, Xintao Chen, Chaowen Xi, Doudou Huang, Yi Deng et al. · 2021 · Frontiers in Pharmacology
60. Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice
    Elena Góméz, J.L. Montero, E. Molina, Luisa Garcı́a-Buey, Marta Casado, Javier Fuentes, Miguel Ángel Simón, Álvaro Díaz‐González, Francisco Jorquera, Rosa Maria Morillas et al. · 2024 · Alimentary Pharmacology & Therapeutics
61. Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses
    Han Yu, Yunzhou Li, Zongying Xu, Dingnan Wang, Shaohua Shi, Huifang Deng, Baihui Zeng, Zhili Zheng, Lili Sun, Xiulan Deng et al. · 2018 · International Journal of Molecular Medicine
62. Stimulation of cholesterol biosynthesis in mitochondrial complex I-deficiency lowers reductive stress and improves motor function and survival in mice
    Tom J.J. Schirris, Sergio Rossell, Ria de Haas, Sanne J.C.M. Frambach, Charlotte A. Hoogstraten, G. Herma Renkema, Julien Beyrath, Peter H.G.M. Willems, Martijn A. Huynen, Jan A.M. Smeitink et al. · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
63. Emerging pharmacologic therapies for primary sclerosing cholangitis
    Angela Cheung, Konstantinos N. Lazaridis, Nicholas F. LaRusso, Gregory James Gores · 2017 · Current Opinion in Gastroenterology
64. HFD-induced TRAF6 upregulation promotes liver cholesterol accumulation and fatty liver development via EZH2-mediated miR-429/PPARα axis
    Zhi Zhang, Huiqing Wen, Bangjian Peng, Jun Weng, Fanhong Zeng · 2021 · Molecular Therapy — Nucleic Acids
65. Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities
    Huiping Zhou, Yi Huang, Chen Chen, Meiyi Song, Phillip B. Hylemon · 2026 · Pharmacological Reviews
66. Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis
    Marco Carbone, Alessio Gerussi, Vincenzo Cardinale, Nora Cazzagon, Valentina Cossiga, Ana Lleò, Giuseppe Marrone, Marco Marzioni, Antonio Moschetta, Luca Muratori et al. · 2024 · Digestive and Liver Disease
67. Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
    Tom H. Karlsen, Kristin Kaasen Jørgensen, Annika M Bergquist · 2024 · Hepatology
68. Protective effect of phosphatidylcholine on lysophosphatidylcholine‐induced cellular senescence in cholangiocyte
    Toshikazu Ohigashi, Keishi Kanno, Akiko Sugiyama, Phuong Thao Nguyen, Nobusuke Kishikawa, Yuichiro Otani, Tomoki Kobayashi, Hiroaki Matsuo, Susumu Tazuma · 2019 · Journal of Hepato-Biliary-Pancreatic Sciences
69. Da-Huang-Xiao-Shi decoction protects against3, 5-diethoxycarbonyl-1,4-dihydroxychollidine-induced chronic cholestasis by upregulating bile acid metabolic enzymes and efflux transporters
    Haoyu Xue, Su Fang, Min Zheng, Jiasheng Wu, Hongyu Li, Mengdie Zhang, Yuanyuan Li, Tianming Wang, Rong Shi, Yueming Ma · 2020 · Journal of Ethnopharmacology
70. Pterostilbene Alleviates Cholestasis by Promoting SIRT1 Activity in Hepatocytes and Macrophages
    Chuanrui Ma, Jiaqing Xiang, Guixiao Huang, Yaxi Zhao, Xinyu Wang, Han Wu, Kewei Jiang, Zhen Liang, Lin Kang, Guangyan Yang et al. · 2021 · Frontiers in Pharmacology
71. Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
    Guilherme Grossi Lopes Cançado, Cláudia Alves Couto, Laura Vilar Guedes, Michelle Harriz Braga, Débora Raquel Benedita Terrabuio, Eduardo Luiz Rachid Cançado, Maria Lúcia Gomes Ferraz, Cristiane Alves Villela‐Nogueira, Mateus Jorge Nardelli, Luciana Costa Faria et al. · 2022 · Frontiers in Pharmacology
72. Activation of PPARα decreases bile acids in livers of female mice while maintaining bile flow and biliary bile acid excretion
    Youcai Zhang, Andrew J. Lickteig, Iván L. Csanaky, Curtis D. Klaassen · 2017 · Toxicology and Applied Pharmacology
73. The role of invariant natural killer T cells in experimental xenobiotic-induced cholestatic hepatotoxicity
    Cheng Nong, Mengzhi Zou, Rufeng Xue, Li Bai, Li Liu, Zhenzhou Jiang, Lixin Sun, Xin Huang, Luyong Zhang, Xinzhi Wang · 2019 · Biomedicine & Pharmacotherapy
74. Bile Acid-Induced Liver Injury in Cholestasis
    Tiangang Li, John Y.L. Chiang · 2017 · Springer eBooks
75. Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
    Yangfan Chen, Ruofei Chen, Haiyan Li, Zongwen Shuai · 2025 · Immunologic Research
76. Exploration of the Molecular Basis of Forsythia Fruit in the Prevention and Treatment of Cholestatic Liver Injury through Network Pharmacology and Molecular Docking
    Ke Fu, Yanzhi Li, Shu Dai, Yunxia Li · 2023 · Nutrients
77. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials
    Behrad Saeedian, Nastaran Babajani, Tannaz Bagheri, Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji · 2025 · BMC Gastroenterology
78. Gene Therapy for Acquired and Genetic Cholestasis
    Javier Martínez-García, Angie Molina, Gloria González‐Aseguinolaza, Nicholas D. Weber, Cristian Smerdou · 2022 · Biomedicines
79. RETRACTED: Molecular insights into experimental models and therapeutics for cholestasis
    Wenwen Zhang, Hefei Wu, Shiman Luo, Xiaohua Lu, Xiyue Tan, Wen Li, Xiao Ma, Thomas Efferth · 2024 · Biomedicine & Pharmacotherapy · Retracted
80. Triclosan exposure causes abnormal bile acid metabolism through IL-1β-NF-κB-Fxr signaling pathway
    Jing Liu, Fang Xu, Mingzhu Guo, Yang Song · 2024 · Ecotoxicology and Environmental Safety
81. Proposed therapies in primary biliary cholangitis
    Annarosa Floreani, Ying Hui Sun, Zheng Sheng Zou, Baosen Li, Nora Cazzagon, Christopher L. Bowlus, Merrill Eric Gershwin · 2015 · Expert Review of Gastroenterology & Hepatology
82. The effect of Crocin on TFAM and PGC-1α expression and Catalase and Superoxide dismutase activities following cholestasis-induced neuroinflammation in the striatum of male Wistar rats
    Mohammad-Reza Eteghadi, Mohammad Nasehi, Salar Vaseghi, Saeed Hesami-Tackallou · 2021 · Metabolic Brain Disease
83. Triptolide increases resistance to bile duct ligation-induced liver injury and fibrosis in mice by inhibiting RELB
    Zihang Yuan, Jie Wang, Haoran Zhang, Yingying Miao, Qianhui Tang, Ziqiao Yuan, Cheng Nong, Zhicheng Duan, Luyong Zhang, Zhenzhou Jiang et al. · 2022 · Frontiers in Nutrition
84. A novel local alignment algorithm for Multilayer networks
    Marianna Milano, Pietro Cinaglia, Pietro Hiram Guzzi, Mario Cannataro · 2023 · Informatics in Medicine Unlocked
85. Coupling an Artificial Receptor with Macrophage Membrane for Targeted and Synergistic Treatment of Cholestasis
    Qiaoxian Huang, Zong‐Ying Hu, Shuwen Guo, Dong‐Sheng Guo, Ruibing Wang · 2022 · Supramolecular Materials
86. Prevention of Cell Growth by Suppression of Villin Expression in Lithocholic Acid-Stimulated HepG2 Cells
    Munetaka Ozeki, Wulamujiang Aini, Aya Miyagawa‐Hayashino, Keiji Tamaki · 2018 · Journal of Histochemistry & Cytochemistry
87. TianJiu therapy for α-naphthyl isothiocyanate-induced intrahepatic cholestasis in rats treated with fresh Ranunculus sceleratus L.
    Zhiyong Zhang, Yiru Miao, Min Xu, Wenming Cheng, Chuanyan Yang, Xiangjian She, Qianqian Geng, Qunlin Zhang · 2019 · Journal of Ethnopharmacology
88. Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
    Bo Shen, Cui Zhou, Tianyi Gu, Zhenyang Shen, Yuecheng Guo, Weiming Dai, Yang Liu, Jie Zhang, Lungen Lu, Hui Dong · 2022 · Frontiers in Pharmacology
89. Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition
    Roger Bentanachs, Lluïsa Miró, Rosa María Sánchez, Patricia Ramírez-Carrasco, Concepció Amat, Marta Alegret, Anna Pérez, Núria Roglans, Juan Carlos Laguna · 2024 · Biomedicine & Pharmacotherapy
90. Fenofibrate Attenuates Radiation-Induced Oxidative Damage to the Skin through Fatty Acid Binding Protein 4 (FABP4)
    Chuntang Sun, Bin Song, Wenjiong Sheng, Daojiang Yu, Tingyi Yang, Fenghao Geng, Kai Fang, Yang Jiao, Jie Zhang, Shuyu Zhang · 2022 · Frontiers in Bioscience-Landmark
91. Gamma‐glutamyl transferase predicts pemafibrate treatment response in non‐alcoholic fatty liver disease
    Yusuke Takahashi, Yuya Seko, Kanji Yamaguchi, Kento Takeuchi, Kota Yano, Seita Kataoka, Michihisa Moriguchi, Yoshito Itoh · 2023 · Journal of Gastroenterology and Hepatology
92. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease
    Hideyuki Tamai, Jumpei Okamura · 2022 · Hepatology Research
93. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Lin Lee Wong, Vinod S. Hegade, David E. Jones · 2017 · Digestive Diseases
94. Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia
    Houshan Yao, Huilin Xu, Shi Qiu, Jiani Chen, Zeshuai Lin, Jiawei Zhu, Xiaomeng Sun, Qianmin Gao, Xintao Chen, Chaowen Xi et al. · 2022 · Pharmacological Research
95. Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
    Claudia Daniela Fuchs, Emina Halilbasic, Michael A Trauner · 2017 · Clinical Liver Disease
96. Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
    Filippo Gabrielli, Eleonora Crepaldi, Alessia Cavicchioli, Marco Rivi, Arianna A.C. Costanzo, Carmela Cursaro, Pietro Andreoné · 2024 · Biomolecules
97. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid
    Albert Rodrigo Parés · 2015 · Digestive Diseases
98. Basal PPARα inhibits bile acid metabolism adaptation in chronic cholestatic model induced by α-naphthylisothiocyanate
    Huiying Hua, Manyun Dai, Yishuang Luo, Hante Lin, Gang-Ming Xu, Xiaowei Hu, Liping Xu, Haoyue Zhang, Zhiyuan Tang, Liming Chang et al. · 2018 · Toxicology Letters
99. Thyroid Dysfunction and Cholesterol Gallstone Disease
    Irina Kube‐Golovin, Denise Zwanziger · 2019 · Experimental and Clinical Endocrinology & Diabetes
100. Gallstone and Gallbladder Disease: Biliary Tract and Cholangiopathies
     Ludovica Ceci, Yuyan Han, Kelsey Krutsinger, Leonardo Baiocchi, Nan Wu, Debjyoti Kundu, Konstantina Kyritsi, Tianhao Zhou, Eugenio Gaudio, Heather Francis et al. · 2023 · Comprehensive physiology